cyclovirobuxine-d and Diabetic-Cardiomyopathies

Diabetic cardiomyopathy (DCM) is the principal cause of death in people with diabetes. However, there is currently no effective strategy to prevent the development of DCM. Although cyclovirobuxine D (CVB-D) has been widely used to treat multiple cardiovascular diseases, the possible beneficial effects of CVB-D on DCM remained unknown. The present aim was to explore the potential effects and underlying mechanisms of CVB-D on DCM. We explored the effects of CVB-D in DCM by using high fat high sucrose diet and streptozotocin-induced rat DCM model. Cardiac function and survival in rats with DCM were improved via the amelioration of oxidative damage after CVB-D treatment. Our data also demonstrated that pre-treatment with CVB-D exerted a remarkable cytoprotective effect against high glucose -or H

Topics: Animals; Animals, Newborn; Antioxidants; Cell Nucleus; Cells, Cultured; Diabetic Cardiomyopathies; Drugs, Chinese Herbal; Female; Glucose; Heart Function Tests; Hydrogen Peroxide; Models, Biological; Myocytes, Cardiac; NF-E2-Related Factor 2; Oxidation-Reduction; Oxidative Stress; Protein Transport; Rats, Sprague-Dawley